Compare Marvell Technology Inc (MRVL) vs TG Therapeutics Inc (TGTX) Price & Performance

Marvell Technology (MRVL) trades at $274.66, down 3.52% on the day, but maintains strong analyst support with 84% buy ratings and a $327.86 consensus price target. The stock shows bullish technical signals with support at $267 and resistance at $282, while recent earnings beats and projected revenue growth to $9.5B in 2026 highlight fundamental momentum. Management's raised 2028 revenue guidance to $18B and major hyperscaler deals underscore the company's positioning in AI infrastructure.

Outlook remains positive driven by AI chip demand and custom silicon growth, though high valuations (P/E 90.95) and margin pressures present risks. The stock offers significant upside to analyst targets but requires monitoring of execution against aggressive growth forecasts and competitive dynamics in the semiconductor space.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.